Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Pediatrics

Background:

• Pediatric-onset multiple sclerosis (POMS) is a rare but distinct form of MS.
• POMS presents different diagnostic and treatment challenges compared to adult-onset MS.
• POMS often exhibits more active disease than adult-onset MS.

Purpose of the Study:

• To review clinical and radiographic presentations of POMS.
• To explore differences in natural history and long-term outcomes between POMS and adult-onset MS.
• To introduce and evaluate the high-efficacy early treatment (HEET) strategy for POMS.

Main Methods:

• Review of clinical and radiographic presentations in POMS.
• Comparison of POMS and adult-onset MS natural histories and outcomes.
• Analysis of available disease-modifying therapies (DMTs) for POMS.
• Introduction of the HEET strategy for POMS treatment.

Main Results:

• POMS is rarer than adult-onset MS but often presents with more active disease.
• Current guidelines often recommend off-label, lower-efficacy DMTs for POMS.
• The HEET strategy proposes using high-efficacy, intravenously infused DMTs as first-line therapy.

Conclusions:

• The HEET strategy offers a novel approach to managing POMS.
• High-efficacy early treatment may be more beneficial for POMS than current guidelines suggest.
• Prospective studies are needed to validate the HEET strategy, with treatment decisions made collaboratively.